Braiin Limited

$7.27 ▼ -10.8%
2026-06-06 06:56:01
NGM: BRAI

Explore Braiin Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap
$1.19 B
Current Price
$7.27
52W High / Low
$98.99 / $6.62
Stock P/E
Book Value
$-0.11
Dividend Yield
ROCE
-8.29%
ROE
-26.06%
Face Value
EPS
$-0.14
Exp Qtr EPS
Sector
Technology

BRAI — Monthly Price History

Adjusted close price  ·  Hover to see price & month

Pros

  • Balance sheet leverage appears manageable.
  • Short-term liquidity looks comfortable.

Cons

  • Return on equity is on the weaker side.
  • Capital efficiency is modest.
  • Operating margin is thin.
  • Net margin is relatively low.

Sift Stocks

S.No. Name Price P.E. Market Cap Div Yld % ROCE ROE 52Week High/ Low Book Value
1. Arista Networks, Inc. $154.27 56.19 $209.04 B 27.4% 30.58% $179.8 / $85.58 $9.85
2. Western Digital Corporation $511.72 31.45 $204.78 B 0.14% 24.81% 90.82% $602.54 / $54.22 $15.97
3. Seagate Technology Holdings plc $847.47 79.91 $190.03 B 0% 35.63% 172.59% $966.8 / $124.63 $0.52
4. Super Micro Computer, Inc. $41.64 20.08 $25.04 B 10.73% 18.22% $62.36 / $19.48 $10.61
5. HP Inc. $25.58 9.16 $23.38 B 4.56% 28.97% 16.85% $29.65 / $17.56 $15.39
6. Everpure Inc $72.17 119.06 $22.41 B 4.15% 13.91% $100.59 / $50.2 $4.38
7. IonQ, Inc. $56.78 64.77 $21.19 B -9.9% 10.72% $84.64 / $25.89 $1.73

Quarterly Results

Figures shown in M / B

Sales
Operating Profit
Net Profit
EPS in Rs

Profit & Loss

Figures shown in M / B

202520242023
Sales73.41 M0 M0 M
Operating Profit-22 M-1.44 M-0.76 M
Net Profit-28.86 M-1.72 M-0.78 M
EPS in Rs-0.14-0.01-0

Balance Sheet

Figures shown in M / B

202520242023
Total Assets290.28 M0.84 M1.54 M
Total Liabilities65.98 M3.67 M2.67 M
Equity224.31 M-2.83 M-1.13 M
Current Assets39.24 M0.7 M1.25 M
Current Liabilities24.78 M3.67 M2.69 M

Cash Flow

Last available yearly cash flow history

202520242023
Operating CF
Investing CF-0.02 M-0 M-0.31 M
Financing CF0.72 M0.06 M1.28 M
Free CF-1.18 M-0.71 M-0.61 M
Capex-0 M-0.31 M

5Y Margin & Growth History

Last 5 years of annual financial statement data.

202520242023
Revenue Growth %
Earnings Growth %-1582.49%-120.48%
Profit Margin %-39.31%
Operating Margin %-29.97%
Gross Margin %31.59%
EBITDA Margin %-20.72%

Dividend & Split History

Latest dividend payments and stock split events.

Dividend History

No dividend history available.

Stock Splits

DateSplit
2026-04-291:3

Shareholding Pattern

Shares and value shown in M / B

Shareholding data not available.

Frequently Asked Questions — Braiin Limited

Will Braiin Limited stock hit $9 in 2026?

Braiin Limited (BRAI) is currently trading at $7.27, with a 52-week range of $6.62 to $98.99. Reaching the $9 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Whether Braiin Limited can reach $9 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Technology space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Short-term price predictions carry significant uncertainty — stock prices can be influenced by factors ranging from quarterly earnings surprises to global macroeconomic events. Use the BRAI Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Is Braiin Limited stock worth buying at $7.27?

Whether Braiin Limited (BRAI) is worth buying at $7.27 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.

Profitability & efficiency: Braiin Limited has a Return on Capital Employed (ROCE) of -8.3%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at -26.1%.

Financial health: The Debt-to-Equity ratio of 0.02 indicates a conservative balance sheet with more equity than debt, reducing financial risk.

Analyst view: Analyst estimates are not currently available for BRAI. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

What is the analyst price target for Braiin Limited (BRAI) in 2026?

Analyst price target data for Braiin Limited (BRAI) is not currently available on StockSifting. Analyst coverage and price targets are typically published by brokerage research desks for widely followed stocks, and are updated regularly after earnings results or major corporate events. Check back for the latest estimates, or explore BRAI's financial ratios, historical returns, and fundamental data available on this page to form your own view.

What will Braiin Limited stock be worth in 2029?

Projecting Braiin Limited (BRAI)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the BRAI Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.